News | March 06, 2024
Bayer strengthens pharma portfolio with new cardiology drug acoramidis
Acquisition of exclusive commercialization rights for European markets
Acquisition of exclusive commercialization rights for European markets
iSolveSM information on demand is the result of our focus on customer relationship
An accomplished R&D leader and champion of the application of AI to drug discovery
This turn valve is considered revolutionary because it supports back-to-back drug infusion through the same device
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
The new ECO grade is made using renewable feedstock
The product has been in-licensed from Strides and will be commercialized by Amneal
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Subscribe To Our Newsletter & Stay Updated
